5:59 PM
 | 
Oct 03, 2012
 |  BC Extra  |  Clinical News

Merck's DPP-4 inhibitor meets diabetes endpoints

Merck & Co. Inc. (NYSE:MRK) said once-weekly oral MK-3102 met the primary endpoint of reducing HbA1c from baseline to week 12 vs. placebo in a Phase IIb trial to treat Type II diabetes....

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >